عنوان النشاط
السُميّة الدموية الناتجة عن الميثوتريكسيت
methotrexate related hematological toxicity
الجهة المنظمة
جامعة بغداد / كلية الصيدلة
تأريخ الانعقاد
2026-09-15 2026-09-15
التخصص
العلوم الطبية والصحية
مكان الانعقاد
كلية الصيدلة
نبذة مختصرة
Methotrexate, an antimetabolite and folate antagonist, can cause significant hematological toxicity through inhibition of DNA synthesis in rapidly dividing bone marrow cells. This results in myelosuppression manifesting as anemia, leukopenia/neutropenia, and thrombocytopenia, which increase risks of fatigue, infections, and bleeding. Toxicity is dose-dependent and worsened by renal impairment or drug interactions. Regular CBC monitoring and folinic acid (leucovorin) rescue are essential to prevent severe complications Methotrexate, an antimetabolite and folate antagonist, can cause significant hematological toxicity through inhibition of DNA synthesis in rapidly dividing bone marrow cells. This results in myelosuppression manifesting as anemia, leukopenia/neutropenia, and thrombocytopenia, which increase risks